Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report)’s share price crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day moving average of $302.03 and traded as low as $300.55. Ligand Pharmaceuticals shares last traded at $301.71, with a volume of 187,061 shares trading hands.
Specifically, Director Martine Zimmermann sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total transaction of $636,340.00. Following the sale, the director owned 1,782 shares in the company, valued at approximately $566,978.94. This trade represents a 52.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Kozarich sold 500 shares of Ligand Pharmaceuticals stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the sale, the director directly owned 42,122 shares of the company’s stock, valued at $13,689,650. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In related news, Director Jason Aryeh sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total value of $960,150.00. Following the completion of the transaction, the director directly owned 105,476 shares in the company, valued at approximately $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on LGND shares. Oppenheimer reissued an “outperform” rating and issued a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Leerink Partners assumed coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 price objective on the stock. Barclays boosted their target price on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating and set a $358.00 price target on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Finally, Citigroup lifted their price target on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $355.38.
Ligand Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.19 and a current ratio of 1.22. The business has a 50 day moving average price of $302.13 and a two-hundred day moving average price of $259.07. The company has a market cap of $5.88 billion, a P/E ratio of 131.17, a price-to-earnings-growth ratio of 5.27 and a beta of 1.16.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The company had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. During the same period in the prior year, the business posted $3.09 EPS. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.
Institutional Investors Weigh In On Ligand Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LGND. Castleark Management LLC lifted its stake in Ligand Pharmaceuticals by 0.7% in the third quarter. Castleark Management LLC now owns 62,463 shares of the biotechnology company’s stock worth $19,512,000 after acquiring an additional 420 shares during the period. Quarry LP purchased a new position in Ligand Pharmaceuticals during the 3rd quarter valued at $312,000. Aquatic Capital Management LLC increased its position in Ligand Pharmaceuticals by 838.2% during the 3rd quarter. Aquatic Capital Management LLC now owns 4,269 shares of the biotechnology company’s stock valued at $1,334,000 after purchasing an additional 3,814 shares during the period. Goldman Sachs Group Inc. raised its holdings in Ligand Pharmaceuticals by 14.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 370,529 shares of the biotechnology company’s stock worth $115,742,000 after purchasing an additional 47,284 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in Ligand Pharmaceuticals by 2.5% in the 3rd quarter. Cetera Investment Advisers now owns 3,833 shares of the biotechnology company’s stock worth $1,197,000 after purchasing an additional 95 shares in the last quarter. 91.28% of the stock is currently owned by institutional investors.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
